Skip to content

Clinical trials

Endometrial Neoplasms trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Endometrial Neoplasms Country / region: United Kingdom Clear all

110 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20012
20021
20031
20051
20061
20072
20081
20094
20102
20113
20122
20132
20142
20155
20164
20178
20186
20197
20204
202110
202210
20235
202411
20256
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed39
Recruiting25
Unknown status15
Active, not recruiting14
Terminated13
Not yet recruiting2
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca8
Imperial College London8
Royal Marsden NHS Foundation Trust6
European Organisation for Research and Treatment of Cancer - EORTC5
Merck Sharp & Dohme LLC5
Seagen Inc.5
University College, London4
Cancer Research UK3
Institute of Cancer Research, United Kingdom3
Royal Cornwall Hospitals Trust3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Endometrial Neoplasms110
Ovarian Neoplasms43
Uterine Cervical Neoplasms30
Carcinoma, Non-Small-Cell Lung19
Neoplasms17
Stomach Neoplasms16
Colorectal Neoplasms13
Breast Neoplasms12
Prostatic Neoplasms12
Urinary Bladder Neoplasms12

Trials

Showing 1 to 25 of 110. Each trial links to its page on Pharma Observatory.

10 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.